None
Quote | Propanc Biopharma (OTCMKTS:PPCBD)
Last: | $0.055 |
---|---|
Change Percent: | 50.0% |
Open: | $0.04 |
Close: | $0.055 |
High: | $0.065 |
Low: | $0.04 |
Volume: | 316,767 |
Last Trade Date Time: | 06/21/2023 03:00:00 am |
News | Propanc Biopharma (OTCMKTS:PPCBD)
Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the Company’s strategic pharma partnering init...
PRP Dosing Patent Validated in 12 Countries Across Europe & Method to Treat Cancer Stem Cells Receives Notice of Allowance from European Patent Office Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical comp...
Message Board Posts | Propanc Biopharma (OTCMKTS:PPCBD)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Propanc Biopharma Company Name:
PPCBD Stock Symbol:
OTCMKTS Market:
Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the Company’s strategic pharma partnering init...
PRP Dosing Patent Validated in 12 Countries Across Europe & Method to Treat Cancer Stem Cells Receives Notice of Allowance from European Patent Office Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical comp...
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today on the progress of the Company, recent de...